Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials

IMPORTANCE: For men with metastatic castration-resistant prostate cancer (mCRPC) whose condition is responding to enzalutamide, new unconfirmed bone lesions detected at posttreatment scinitigraphy may reflect an osteoblastic reaction that represents healing, known as pseudoprogression, which can lea...

Descripción completa

Detalles Bibliográficos
Autores principales: Armstrong, Andrew J., Al-Adhami, Mohammed, Lin, Ping, Parli, Teresa, Sugg, Jennifer, Steinberg, Joyce, Tombal, Bertrand, Sternberg, Cora N., de Bono, Johann, Scher, Howard I., Beer, Tomasz M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990871/
https://www.ncbi.nlm.nih.gov/pubmed/31830211
http://dx.doi.org/10.1001/jamaoncol.2019.4636

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990871/
https://www.ncbi.nlm.nih.gov/pubmed/31830211
http://dx.doi.org/10.1001/jamaoncol.2019.4636

Ejemplares similares